Cowen & Co.

Cowen and Leerink rated Quanterix at Outperform while JP Morgan initiated coverage with an Overweight rating — the banks managed the company's $74 million IPO.

In a note, Cowen analyst Doug Schenkel said the company has had trouble meeting its targets and suggested it pursue a strategic sale of its nCounter platform.

The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.

The investment bank gave shares of the molecular diagnostics firm an Outperform rating and a price target of $20 per share.

Cowen & Co. upgraded Fluidigm to an Outperform rating, while William Blair upgraded Hologic also to Outperform. 

NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded Hologic's stock from Outperform to Market Perform and lowered its price target on the shares.

NEW YORK (GenomeWeb News) – Investment bank Cowen & Co. today upgraded shares of Qiagen to Market Perform, citing the firm's recently acquired Ingenuity business, stabilization in its US human papillomavirus business, and Qiagen's movement toward higher growth businesses.

NEW YORK (GenomeWeb News) – Cowen & Co. today started covering Bruker, giving it an Outperform rating and a $21 price target.

NEW YORK (GenomeWeb News) – Investment bank Cowen & Co. today initiated coverage of molecular diagnostics companies GenMark Diagnostics and Nanosphere with Outperform ratings.

NEW YORK (GenomeWeb News) – Citing a recent run up in Life Technologies' stock fueled by speculation that it may be positioning itself to be bought, investment bank Cowen & Co. today downgraded the Carlsbad, Calif.-based firm to Neutral from Outperform.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.